Sonova (OTCMKTS:SONVY) Stock Rating Lowered by UBS Group

Sonova (OTCMKTS:SONVY) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other analysts have also issued reports about the stock. The Goldman Sachs Group raised shares of Sonova from a “hold” rating to a “buy” rating in a research note on Thursday, October 8th. Citigroup reaffirmed a “sell” rating on shares of Sonova in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Sonova Trading Down 1.1%

SONVY opened at $68.42 on Monday. The business has a fifty day moving average of $61.51 and a 200 day moving average of $53.34. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.43 and a current ratio of 1.75. Sonova has a 52-week low of $42.26 and a 52-week high of $69.66.

Sonova Company Profile

Sonova Holding AG is a Switzerland-based hearing-care company that develops, manufactures and distributes solutions for people with hearing loss. Its portfolio includes hearing aids, cochlear implants, hearing implants, wireless communication products and related accessories and services.

The company markets products under several brands, including Phonak, Unitron and Advanced Bionics. Sonova also operates hearing-care businesses and retail networks that provide hearing assessments, device fitting, rehabilitation support and after-sales services.